Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
Authors:
Open Access
- 26 February 2022
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (6) , 2849-2854
Abstract
Outcomes of 109 hospitalized COVID‐19 patients who received at least one vaccine dose 14 or more days prior the disease onset were retrospectively compared to control cohort of 109 age, sex, and Charlson comorbidity index‐matched patients chosen among 2990 total hospitalized patients in our tertiary‐level institution in a period from January to June 2021. Among 109 vaccinated patients, 84 patients were partially and 25 fully vaccinated. Vaccinated patients experienced significantly lower 30 days mortality (30% vs. 49%; hazard ratio [HR]: 0.56 [0.37–0.85]; p = 0.008), less frequently required high flow oxygen therapy (17% vs. 34%; HR: 0.45 [0.26–0.76]; p = 0.005), and mechanical ventilation (8% vs. 18%; HR: 0.41 [0.20–0.88]; p = 0.027) in comparison to the matched cohort of unvaccinated patients. More favorable survival was observed in patients receiving vector in comparison to messenger RNA (mRNA) vaccine types in unadjusted analysis (30 days mortality 18% vs. 40%; HR: 0.45 [0.25–0.79]; p = 0.034). In the multivariable Cox regression analysis model both mRNA (HR: 0.59 [0.36–0.98]; p = 0.041) and vector vaccine types (HR: 0.30 [0.15–0.60]; p < 0.001) were associated with improved survival in comparison to unvaccinated patients, independently of age (HR: 1.03 [1.01–1.06]; p = 0.011), male sex (HR: 1.78 [1.14–2.76]; p = 0.010), severity of illness (HR: 2.06 [1.36–3.10]; p < 0.001) and functional status on admission (HR: 1.42 [1.07–1.85]; p = 0.013).Keywords
This publication has 12 references indexed in Scilit:
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Vaccination status and COVID-19 related mortality: A hospital based cross sectional studyMedical Journal Armed Forces India, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020